Advertisement

The ORCHIDEE study: gathering new evidence on the use of everolimus in clinical practice

Abstract

Randomized clinical trials are the gold standard to test the efficacy of an intervention within a specified patient population. However, the results of the trials may not be generalizable to routine clinical practice. Observational cohort studies may provide information that complements trial results. Targeted therapies are characterized by tolerability profiles that may differ from those of ‘traditional’ chemotherapy. Therefore, the post-approval evaluation of these drugs by large, well-designed observational cohort studies in real life populations is warranted. Everolimus is an orally-administered inhibitor of the mammalian target of rapamycin. A number of observational cohort studies have been conducted to characterize the effectiveness and safety of everolimus in clinical practice. In particular, the ORCHIDEE study was designed to identify factors predictive of favorable outcome in patients treated with everolimus such as secondline treatment for metastatic renal cell carcinoma after failure of a first-line treatment with a VEGF TKI. ORCHIDEE is a multicenter, single-arm, phase IV study. The study will enroll approximately 200 metastatic renal cell carcinomametastatic renal cell carcinoma patients from 20 Italian centers over a 24-month period.

Tumori 2014; 100(6): e290 - e292

Article Type: ORIGINAL RESEARCH ARTICLE

DOI:10.1700/1778.19300

Authors

Mimma Rizzo, Giacomo Cartenì, Giovanni Pappagallo, Lital Hollander, Irene Floriani

Article History

This article is available as full text PDF.

  • If you are a Subscriber, please log in now.

  • Article price: Eur 36,00
  • You will be granted access to the article for 72 hours and you will be able to download any format (PDF or ePUB). The article will be available in your login area under "My PayPerView". You will need to register a new account (unless you already own an account with this journal), and you will be guided through our online shop. Online purchases are paid by Credit Card through PayPal.
  • If you are not a Subscriber you may:
  • Subscribe to this journal
  • Unlimited access to all our archives, 24 hour a day, every day of the week.

Authors

  • Rizzo, Mimma [PubMed] [Google Scholar]
    UOC di Oncologia, Azienda Ospedaliera “A Cardarelli”, Naples, Italy
  • Cartenì, Giacomo [PubMed] [Google Scholar]
    UOC di Oncologia, Azienda Ospedaliera “A Cardarelli”, Naples, Italy
  • Pappagallo, Giovanni [PubMed] [Google Scholar]
    UOC di Oncologia & Ematologia Oncologica, Azienda Sanitaria ULSS 13, Mirano (Venice), Italy
  • Hollander, Lital [PubMed] [Google Scholar]
    Laboratory of Clinical Research, IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
  • Floriani, Irene [PubMed] [Google Scholar]
    Laboratory of Clinical Research, IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

No supplementary material is available for this article.